• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $VRCA

    Verrica Pharmaceuticals Inc.

    Subscribe to $VRCA
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; which has completed phase II clinical trial for treating common warts; and that is in phase II clinical trial for the treatment of external genital warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

    IPO Year: 2018

    Exchange: NASDAQ

    Website: verrica.com

    Peers

    $MEIP

    Recent Analyst Ratings for Verrica Pharmaceuticals Inc.

    DatePrice TargetRatingAnalyst
    11/6/2024Buy → Neutral
    H.C. Wainwright
    11/5/2024Outperform → Sector Perform
    RBC Capital Mkts
    7/25/2023$10.00Hold → Buy
    Needham
    3/22/2023$10.00Buy
    Jefferies
    2/13/2023$4.00 → $11.00Sector Perform → Outperform
    RBC Capital Mkts
    5/25/2022$16.00 → $4.00Outperform → Sector Perform
    RBC Capital Mkts
    3/10/2022$20.00Buy
    Brookline Capital
    3/3/2022$20.00 → $18.00Buy
    Needham
    9/22/2021$24.00 → $20.00Buy
    HC Wainwright & Co.
    9/21/2021$19.00 → $16.00Outperform
    RBC Capital
    See more ratings

    Verrica Pharmaceuticals Inc. SEC Filings

    See more
    • SEC Form DEFR14A filed by Verrica Pharmaceuticals Inc.

      DEFR14A - Verrica Pharmaceuticals Inc. (0001660334) (Filer)

      4/30/25 6:06:32 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Verrica Pharmaceuticals Inc.

      8-K - Verrica Pharmaceuticals Inc. (0001660334) (Filer)

      4/25/25 4:21:12 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Verrica Pharmaceuticals Inc.

      DEFA14A - Verrica Pharmaceuticals Inc. (0001660334) (Filer)

      4/22/25 7:18:16 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Verrica Pharmaceuticals Inc.

      DEF 14A - Verrica Pharmaceuticals Inc. (0001660334) (Filer)

      4/22/25 7:15:42 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Verrica Pharmaceuticals Inc.

      8-K - Verrica Pharmaceuticals Inc. (0001660334) (Filer)

      4/2/25 4:31:12 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Verrica Pharmaceuticals Inc.

      EFFECT - Verrica Pharmaceuticals Inc. (0001660334) (Filer)

      3/26/25 12:15:14 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-3 filed by Verrica Pharmaceuticals Inc.

      S-3 - Verrica Pharmaceuticals Inc. (0001660334) (Filer)

      3/11/25 5:05:43 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Verrica Pharmaceuticals Inc.

      10-K - Verrica Pharmaceuticals Inc. (0001660334) (Filer)

      3/11/25 4:23:59 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Verrica Pharmaceuticals Inc. (0001660334) (Filer)

      3/11/25 4:15:14 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Verrica Pharmaceuticals Inc.

      8-K - Verrica Pharmaceuticals Inc. (0001660334) (Filer)

      2/21/25 4:15:44 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Verrica Pharmaceuticals Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Corcoran Gavin

      4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      4/2/25 4:32:51 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Corcoran Gavin claimed ownership of 20 shares (SEC Form 3)

      3 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      4/2/25 4:31:50 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CMO Rosenberg Noah L.

      4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      3/26/25 7:10:45 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Rosenberg Noah L.

      3 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      3/26/25 7:08:03 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF LEGAL OFFICER Hayes Christopher G. sold $2,805 worth of shares (4,315 units at $0.65), decreasing direct ownership by 2% to 176,458 units (SEC Form 4)

      4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      3/18/25 6:45:05 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CEO and President Rieger Jayson

      4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      3/18/25 6:45:07 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Chief Medical Officer Goldenberg Gary was granted 50,000 shares, increasing direct ownership by 71% to 120,110 units (SEC Form 4)

      4/A - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      2/6/25 4:15:17 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: CHIEF LEGAL OFFICER Hayes Christopher G. was granted 150,000 shares, increasing direct ownership by 183% to 231,925 units (SEC Form 4)

      4/A - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      2/6/25 4:15:10 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: PRESIDENT AND CEO White Ted was granted 150,000 shares, increasing direct ownership by 116% to 278,789 units (SEC Form 4)

      4/A - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      2/6/25 4:15:07 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: CHIEF FINANCIAL OFFICER Kohler Terry was granted 125,000 shares (SEC Form 4)

      4/A - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      2/6/25 4:15:13 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Verrica Pharmaceuticals Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Stalfort John A Iii bought 1,123,595 shares and received a gift of 50,000 shares, increasing direct ownership by 168% to 1,873,800 units (SEC Form 4)

      4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      11/26/24 4:15:08 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and President Rieger Jayson bought 280,898 shares and received a gift of 50,000 shares, increasing direct ownership by 60% to 882,826 units (SEC Form 4)

      4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      11/26/24 4:15:13 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Manning Paul B bought 22,921,348 shares and gifted 450,000 shares (SEC Form 4)

      4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      11/26/24 4:15:07 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perceptive Advisors Llc bought $2,305,132 worth of shares (321,616 units at $7.17) (SEC Form 4)

      4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      12/29/23 5:27:30 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perceptive Advisors Llc bought $3,256,191 worth of shares (504,652 units at $6.45) (SEC Form 4)

      4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      12/26/23 7:21:16 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perceptive Advisors Llc bought $6,941,716 worth of shares (1,233,931 units at $5.63) (SEC Form 4)

      4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      12/19/23 5:52:31 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Verrica Pharmaceuticals Inc. FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for YCANTH issued to VERRICA PHARMACEUTICALS INC

      Submission status for VERRICA PHARMACEUTICALS INC's drug YCANTH (ORIG-1) with active ingredient CANTHARIDIN has changed to 'Approval' on 07/21/2023. Application Category: NDA, Application Number: 212905, Application Classification: Type 5 - New Formulation or New Manufacturer

      7/21/23 4:54:32 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Verrica Pharmaceuticals Inc. Financials

    Live finance-specific insights

    See more
    • Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

      WEST CHESTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, May 13, 2025, to discuss the Company's financial results for the first quarter ending March 31, 2025, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of

      5/7/25 8:00:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025

      WEST CHESTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, March 11, 2025, to discuss the Company's financial results for the fourth quarter and full year ending December 31, 2024, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-445-7795 (domestic) or 1-785-424-1699 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minut

      3/3/25 7:00:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results

      - Reports YCANTH® revenue, net of $4.9M for second quarter of 2024 along with the expansion of YCANTH's distribution footprint to include Cencora, Inc. as a specialty distributor – - Announces positive preliminary topline results of Phase 2 clinical study of VP-315 for the treatment of patients with basal cell carcinoma – - Continues to progress preparation for global Phase 3 Common Warts trial with initiation expected in 1H 2025 – - Conference Call Scheduled for Today at 8:30 am ET – WEST CHESTER, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical i

      8/14/24 7:45:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024

      WEST CHESTER, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 14, 2024, to discuss the Company's financial results for the second quarter ended June 30, 2024, and provide an overview of topline results from Part 2 of the Phase 2 trial of VP-315 for the treatment of basal cell carcinoma. Individuals may participate in the live call via telephone by dialing 1-800-579-2543 (domestic) or 1-785-424-1789 (international)

      8/6/24 7:30:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results

      – Reports YCANTH® revenue of $3.2M for first quarter of 2024 – – Over 228 million lives now covered to date on commercial insurance, managed Medicaid, Tricare and Federal Employee plans – – Preliminary Phase 2 results for VP-315 in the treatment of basal cell carcinoma (BCC) expected in the second quarter of 2024 – – Conference Call Scheduled for Today at 8:30 am ET – WEST CHESTER, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the first quarter ended March 31, 2024. "The first quarter of 2024

      5/13/24 7:30:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024

      WEST CHESTER, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, May 13, 2024 to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2024. Individuals may participate in the live call via telephone by dialing 1-877-407-4018 (domestic) or 1-201-689-8471 (international) and using the conference ID: 13746100. Participants are asked to dial in 10 minutes before the start of th

      5/8/24 7:30:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results

      – Reports YCANTH™ revenue of $1.9M for fourth quarter and $4.7M for full year 2023 – – Over 200 million lives now covered on commercial insurance and managed Medicaid plans – – Conference Call Scheduled for Today at 8:30 am ET – WEST CHESTER, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the fourth quarter and year ended December 31, 2023. "We continued to make considerable progress with the launch of YCANTH™ during our first full quarter of commercial operations," said Ted White, Verrica's Pr

      2/29/24 7:30:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024

      WEST CHESTER, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, February 29, 2024 to provide a corporate update and discuss the Company's financial results for the fourth quarter and full-year ended December 31, 2023. Individuals may participate in the live call via telephone by dialing 1-877-407-4018 (domestic) or 1-201-689-8471 (international) and using the conference ID: 13744217. Participants are asked to dial in 10 minu

      2/22/24 7:30:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results

      – Strong awareness and interest in prescribing YCANTH™ among dermatologists and pediatricians – – Over 112 million lives covered to date on commercial insurance and managed Medicaid plans – – Conference Call Scheduled for Today at 8:30 am ET – WEST CHESTER, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the third quarter ended September 30, 2023. "Following the U.S Food and Drug Administration approval of YCANTH™ for the treatment of molluscum in July, we continue to build momentum across our c

      11/9/23 7:30:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023

      WEST CHESTER, Pa., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, November 9, 2023, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2023. Individuals may participate in the live call via telephone by dialing 1-877-407-4018 (domestic) or 1-201-689-8471 (international) and using the conference ID: 13741589. Participants are asked to dial in 10 minutes before the

      10/25/23 7:00:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Verrica Pharmaceuticals Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Verrica Pharmaceuticals downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Verrica Pharmaceuticals from Buy to Neutral

      11/6/24 6:25:52 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals downgraded by RBC Capital Mkts

      RBC Capital Mkts downgraded Verrica Pharmaceuticals from Outperform to Sector Perform

      11/5/24 6:29:20 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals upgraded by Needham with a new price target

      Needham upgraded Verrica Pharmaceuticals from Hold to Buy and set a new price target of $10.00

      7/25/23 7:35:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Verrica Pharmaceuticals with a new price target

      Jefferies initiated coverage of Verrica Pharmaceuticals with a rating of Buy and set a new price target of $10.00

      3/22/23 7:39:44 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals upgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts upgraded Verrica Pharmaceuticals from Sector Perform to Outperform and set a new price target of $11.00 from $4.00 previously

      2/13/23 7:24:52 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded Verrica Pharmaceuticals from Outperform to Sector Perform and set a new price target of $4.00 from $16.00 previously

      5/25/22 7:50:16 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Brookline Capital initiated coverage on Verrica Pharmaceuticals with a new price target

      Brookline Capital initiated coverage of Verrica Pharmaceuticals with a rating of Buy and set a new price target of $20.00

      3/10/22 8:40:21 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on Verrica Pharmaceuticals with a new price target

      Needham reiterated coverage of Verrica Pharmaceuticals with a rating of Buy and set a new price target of $18.00 from $20.00 previously

      3/3/22 6:02:42 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Verrica Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Verrica Pharmaceuticals with a rating of Buy and set a new price target of $20.00 from $24.00 previously

      9/22/21 6:04:36 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital reiterated coverage on Verrica Pharmaceuticals with a new price target

      RBC Capital reiterated coverage of Verrica Pharmaceuticals with a rating of Outperform and set a new price target of $16.00 from $19.00 previously

      9/21/21 7:14:18 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Verrica Pharmaceuticals Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

      WEST CHESTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, May 13, 2025, to discuss the Company's financial results for the first quarter ending March 31, 2025, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of

      5/7/25 8:00:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York

      WEST CHESTER, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Citizens Life Sciences Conference in New York City. Citizens Life Sciences Conference, May 7-8, 2025Event details:Date: Wednesday, May 7, 2025Time: 3:00 pm ETLocation: New York Hilton Midtown, New York Participants may access a live webcast of the event by clicking the link here. The webcast can also be accessed in the Invest

      4/30/25 8:00:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025

      – Company generated quarterly sequential growth with Q1 YCANTH® dispensed applicator units rising above 10,000 for the first time in a quarter – – As YCANTH distributor inventory levels have normalized, Company expects that dispensed applicator units will now more closely track demand and gross revenue – WEST CHESTER, Pa., April 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Company experienced strong demand-led growth for YCANTH® in the first quarter of 2025, with the number of dispensed applicato

      4/7/25 8:00:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors

      WEST CHESTER, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Gavin Corcoran, M.D. to its Board of Directors. "We are pleased to welcome Dr. Gavin Corcoran to our Board of Directors," said Jayson Rieger, Ph.D., MBA, President and Chief Executive Officer of Verrica Pharmaceuticals. "Gavin is a highly accomplished pharmaceutical executive with an outstanding track record of successfully developing and launching innovative medicines, as well as creating significant value through strat

      4/2/25 4:05:00 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

      WEST CHESTER, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference. 24th Annual Needham Virtual Healthcare Conference, April 7-10, 2025Event details:Date: Tuesday, April 8, 2025Time: 1:30 pm ETLocation: Virtual Participants may access a live webcast of the event by clicking the link here. The webcast can also be accesse

      3/31/25 8:00:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer

      WEST CHESTER, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Noah L. Rosenberg, M.D., as Chief Medical Officer. "We are excited to welcome Noah Rosenberg to the Verrica team as our new Chief Medical Officer," said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. "As a highly accomplished drug development executive and physician, Noah's deep expertise will significantly help our efforts to establish YCANTH® as the new standard of care for the treatment of mo

      3/26/25 7:00:00 AM ET
      $ESPR
      $TVTX
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

      – Company generated quarterly sequential growth in YCANTH® dispensed applicator units of 12.3% in Q4'24 concurrent with significantly lower operating expenses – – Company reports positive quarterly revenue earlier than previously disclosed expectations, as new demand resulted in Company's primary distribution partner ordering applicators of YCANTH during Q4'24 – – Late-stage pipeline continues to advance with programs in basal cell carcinoma (VP-315) and common warts (VP-102/YCANTH) – – Recently strengthened balance sheet with the November 2024 $42 million public offering – – Conference call scheduled for today at 4:30 pm ET – WEST CHESTER, Pa., March 11, 2025 (GLO

      3/11/25 4:05:00 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025

      WEST CHESTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, March 11, 2025, to discuss the Company's financial results for the fourth quarter and full year ending December 31, 2024, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-445-7795 (domestic) or 1-785-424-1699 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minut

      3/3/25 7:00:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston

      WEST CHESTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference in Boston. TD Cowen 45th Annual Health Care Conference, March 3-5, 2025Event details:Date: Monday, March 3, 2025Time: 2:30 pm ETLocation: Boston, MA Participants may access a live webcast of the event by clicking the link here. The webcast can also be accessed

      2/25/25 4:05:00 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference

      – Presented data includes a 97% Calculated Objective Response Rate (ORR) of study subjects following treatment with VP-315 – Posters highlight the safety data, tolerability data, and antitumor efficacy data of VP-315 for the treatment of basal cell carcinoma as determined by histological clearance WEST CHESTER, Pa., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the presentation of three posters that were presented at the 2025 Winter Clinical Dermatology Conference, which was held from January 17-19, in

      1/21/25 7:00:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Verrica Pharmaceuticals Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Verrica Pharmaceuticals Inc.

      SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

      12/9/24 6:22:49 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Verrica Pharmaceuticals Inc.

      SC 13D/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

      11/26/24 4:15:26 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Verrica Pharmaceuticals Inc.

      SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

      11/14/24 9:32:46 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Verrica Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

      2/14/24 4:47:04 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Verrica Pharmaceuticals Inc.

      SC 13G - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

      2/14/24 9:10:38 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Verrica Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

      2/14/23 2:37:04 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Verrica Pharmaceuticals Inc.

      SC 13D - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

      7/15/22 4:15:28 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Verrica Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

      2/14/22 4:37:09 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Verrica Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

      2/14/22 3:54:03 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Verrica Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

      2/11/22 4:57:36 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Verrica Pharmaceuticals Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition

      – Company reported $0 in product shipments in the third quarter of 2024 and recognized negative net product revenue of $1.9 million, including a provision for product returns of $1.7 million– – Company expects existing distributor inventory to support most demand for dispensed applicator units into the first quarter of 2025 – – Company continues to look for ways to manage expenses and expand access to YCANTH® for the treatment of molluscum contagiosum – – Company announces new senior leadership with appointments of Dr. Jayson Rieger as Chief Executive Officer and John Kirby as Interim Chi

      11/4/24 4:05:00 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals Reports Second Quarter 2021 Financial Results

      WEST CHESTER, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the second quarter ended June 30, 2021. "This quarter, we continued to ramp up commercial preparations for the potential FDA approval of VP-102, our lead product candidate for the treatment of molluscum contagiosum, including strengthening our senior leadership team and ensuring patient access to VP-102 through productive dialogue with medical providers and payors," said Ted White, Verrica's President and Chief Executive Officer. "With a

      8/10/21 7:30:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals Announces Appointment of Terry Kohler as Chief Financial Officer

      Company strengthens management team in anticipation of the potential commercial launch of VP-102, if approved WEST CHESTER, Pa., July 09, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Terry Kohler as Chief Financial Officer. Mr. Kohler is a strategic and operational finance leader with over 20 years of commercial business experience, most recently at a global pharmaceutical company with annual revenues over $2 billion. Mr. Kohler is replacing Brian Davis, who is leaving Verrica to pursue other opportunities. "Te

      7/9/21 7:30:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care